Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014

The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for mos...

Descripción completa

Detalles Bibliográficos
Autor principal: Agazzi, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2015
Materias:
Conference Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341995/
https://www.ncbi.nlm.nih.gov/pubmed/25729427
http://dx.doi.org/10.3332/ecancer.2015.514
_version_ 1782359221635907584
author Agazzi, Alberto
author_facet Agazzi, Alberto
author_sort Agazzi, Alberto
collection PubMed
description The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for most diseases; for instance, anti-PD-1 and CAR-T cells in lymphoproliferative disorders and novel immunomodulatory agents active in the contest of bone marrow milieu in multiple myeloma. On the other hand, in aggressive haematological diseases (AML, ALL), clinical studies demonstrated the feasibility of a more intensive chemotherapy approach in older patients.
format Online
Article
Text
id pubmed-4341995
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-43419952015-02-27 Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014 Agazzi, Alberto Ecancermedicalscience Conference Report The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for most diseases; for instance, anti-PD-1 and CAR-T cells in lymphoproliferative disorders and novel immunomodulatory agents active in the contest of bone marrow milieu in multiple myeloma. On the other hand, in aggressive haematological diseases (AML, ALL), clinical studies demonstrated the feasibility of a more intensive chemotherapy approach in older patients. Cancer Intelligence 2015-02-26 /pmc/articles/PMC4341995/ /pubmed/25729427 http://dx.doi.org/10.3332/ecancer.2015.514 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Conference Report
Agazzi, Alberto
Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014
title Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014
title_full Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014
title_fullStr Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014
title_full_unstemmed Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014
title_short Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014
title_sort report on the 56th ash annual meeting, san francisco, 4–9 december 2014
topic Conference Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341995/
https://www.ncbi.nlm.nih.gov/pubmed/25729427
http://dx.doi.org/10.3332/ecancer.2015.514
work_keys_str_mv AT agazzialberto reportonthe56thashannualmeetingsanfrancisco49december2014

Ejemplares similares